Resultados de la búsqueda 221-230 of 4486 for testosterone

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6-month PFS rate, ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Jacksonville, Fla., Rochester, Minn. The purpose of this study is to evaluate the safety and effectiveness of the da Vinci Surgical Systems in Nipple Sparing ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not ...

  5. JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Jacksonville, Fla. This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...